Clinical HIV Research Unit’s Post

In honor of #WorldTBDay, I am excited to share our new #MMWR summarizing #PEPFAR's global progress to prevent TB in people living with HIV. Read more here: #PreventTB #EndTB

Tuberculosis disease has a significant influence in the context of advanced HIV disease, being among the greatest causes of mortality in people living with HIV. According to the WHO,, an estimated 187 000 people died from HIV-associated TB in 2022. Thus, a better understanding of the current guidance, key clinical issues, and developments in research on TB/HIV is important to improve clinical outcomes. Join: https://buff.ly/4aD7U9X

Global Fund Report 2023 @Tuberculosis 🔹7.1M people were treated for TB in 2023. 🔹 70% TB Treatment and overage 🔹121K People were on treatment for Drug Resistant TB in 2023. 🔹353K pople with HIV & TB were on anti-retroviral therapy (ART). 🔹2M People exposed to TB received TB Preventive Treatment (TPT). 🔹1.7M People living with HIV who are on ART received TB Preventive Treatment (TPT).

A new report released by UNAIDS and Friends of the Global Fight Against AIDS, Tuberculosis and Malaria shows how countries are leveraging their HIV responses to both ensure impact on the HIV response and also to improve broader national health and well-being. The report finds that investing now to end AIDS as a public health threat by 2030 will not only follow through on the commitment to end the pandemic but also magnify the broader health benefits of HIV specific investments. The report profiles six country examples indicating that strengthened HIV responses have contributed to broader health benefits. To read the full report, click on the link: https://lnkd.in/gjPA4c4C

In light of ongoing stakeholder conversations related to The Global Fund allocations for TB, HIV, and malaria, TAG urges a syndemic approach that advocates research + programming with broadest possible benefits. Our statement: https://lnkd.in/eQNxPa4X

The results from this very recent Nordic survey (n=4000) on the knowledge and attitudes towards HIV/AIDS in the era of undetectable = untransmissible was presented last week at the Nordic HIV & Virology Conference in Stockholm. This poster won the Poster Award. The reason is because it shows that ... 51% claim being informed about HIV/AIDS and 71% agree HIV is a manageable chronic disease, still 40% believe transmission is possible under ART, 22% and 9% respectively still believe it is transmissible by kissing or sharing itmes such as plates or glasses! KNOWLEDGE and breaking entrenched (false) believes are probably the most important factors in eleviating stigmas...and it seems we still have some way to go. These data can help get the facts right and help improve awareness, education, and policies. #GileadNordics #MyCompany Janniche Hammer Susanne von Stockenström Juha Vuorte Ellen Moseholm Larsen Aurelie Miglar, Ph.D. Philippa Collins

📢 We need your help! Millions of people are missing out on medical tests that can quickly and accurately diagnose TB, HIV, hepatitis, and other diseases. Why? Because Cepheid and Danaher – the makers of the tests and the company that owns it – vastly overcharge for them. MSF and other healthcare providers use GeneXpert tests to quickly and accurately diagnose people with TB, HIV, and other diseases, so we can administer the right treatment in time. But the high price of these tests means that many low- and middle-income countries can’t afford to test everyone who needs it. A study we conducted shows that Cepheid and Danaher could be charging $5 for each of these medical tests and still make a profit, but instead, they charge up to 400% of that price even in the world’s poorest countries. This #WorldTBDay, help us to get them to drop the price for GeneXpert tests to $5! 👇 https://lnkd.in/dhQeC--7

Ending the HIV Epidemic Data Shows Hits, and Misses Numbers may be boring, but when it comes to matters of life and death, numbers are essential, and quality data is indispensable. The Centers for Disease Control and Prevention (CDC) last week released its most recent HIV Incidence and Prevalence report. The report is based on data from 2018-2022, with the data gathering completed in December 2023. The U.S. is not currently on track to reach Ending the HIV Epidemic (EHE) 2025 and 2030 prevention goals. While progress is being made, there remains much work that needs to be done. Read more: https://lnkd.in/g3-Gs--5

Today is #NationalHepatitisTestingDay. Hepatitis B & Hepatitis C are common liver infections that impact people with HIV. Help raise awareness about #HepB and #HepC by encouraging hepatitis testing. Given the risk of HIV/HCV coinfection, it is important for people with HIV to understand the risk, take steps to prevent infection, and know their status. Treatment is available at Midway Specialty Care Center that can cure HCV and reduce the chance of developing liver damage, liver cancer, or the risk of death. Learn more at https://bit.ly/3N1fHne

As 2024 comes to an end, we applaud #PEPFAR, USAID and Centers for Disease Control and Prevention and the #AmericanPeople for its investment in fighting HIV globally - working shoulder to shoulder with the people affected - and collaborating closely with national and local governments. This investment is saving thousands of human lives every day! In 2025, we must ramp up our investment in the global response to HIV, expanding our people-centered and community-led movement to ensure epidemic control. #PeopleToPeople #PeopleFirst Planet Aid, Inc The Federation Humana People to People Humana Spain ADPP Moçambique ADPP Angola